A Phase 4 interventional study of Eculizumab in Hemoglobinuria, Paroxysmal, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 3 sites in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2018-10-31.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.
Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 17th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 4, and was the 6th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →
eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2009.
This study's enrollment of 7 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 37 across the 18 interventional studies. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca: 3 open now, 7 under way, 2 of them phase 3. Of 26 finished, 18 (69%) have results posted.
Among the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, this one is the 22nd largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2009, is one of 2 in phase 4, and was the 5th registered.
AstraZeneca’s Hemoglobinuria, Paroxysmal studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 35 in Hemoglobinuria, Paroxysmal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) parameter estimates of eculizumab to confirm the dose regimens for pediatric and adolescent participants with PNH.
This was an open-label, multi-center study of eculizumab administered to approximately 6 to 8 pediatric and adolescent participants aged 2 to 17 years with PNH. There were 3 periods in this study (screening, treatment, and post-treatment) with the treatment period having 2 dosing phases (induction and maintenance). If all screening criteria were met, the participant was eligible to enter the treatment period of the study after receiving Neisseria meningitidis (N. men), Streptococcus pneumoniae (S. pneumo), and Haemophilus influenzae (H. influ) vaccinations at least 14 days prior to first dose of study drug, or was vaccinated and received treatment with appropriate antibiotics until 14 days after the vaccinations. Participants received eculizumab intravenously (IV) based on their weight. Eculizumab was administered via an IV infusion at a rate of 5 to 10 milliliters (mL) per kilogram (kg) per hour (hr) (mL/kg/hr) for at least 25 minutes. The planned duration of treatment was 12 weeks with a 4-week induction phase and an 8-week maintenance phase. At the Investigator's and parents/legal guardian's discretion, participants who completed this study with eculizumab could continue treatment with commercially available eculizumab (Soliris®) and were followed in the Soliris® PNH Registry. Participants who stopped study participation before study completion or who did not continue with Soliris® treatment at the completion of the study were followed for 8 weeks and monitored for signs and symptoms of serious hemolysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eculizumab was administered as an IV infusion for 12 weeks. All participants weighed more than 45 kg and received the following weight-based dosing regimen: induction/loading = 600 milligram (mg) weekly x 4; maintenance = 900 mg at Week 5; 900 mg every 2 weeks.
Drug: Eculizumab
5 mg/mL solution in 5% Dextrose
Also known as: Soliris®
Peak And Trough Concentrations Of Eculizumab In Serum At Week 12
Serum concentrations of eculizumab were measured by using a validated enzyme-linked immunosorbent assay (ELISA) method developed at Alexion Pharmaceuticals Bioanalytical Laboratory. The range of the analytical assay was 10 to 600 microgram per milliliter (μg/mL). Peak concentrations were not measured at the early termination (ET) visit.
Time frame: Pre-infusion and 1 hour post-infusion at End of Treatment (EOT) (Day 84 [Week 12]) or ET
Number Of Participants With Treatment-emergent Adverse Events (TEAEs)
A TEAE was defined as any adverse event (AE) not present prior to exposure to eculizumab or any event already present that worsened in either intensity or frequency following exposure to eculizumab. A serious TEAE was defined as any event that resulted in death, was immediately life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect. Related TEAEs were considered by investigators to be definitely, probably, or possibly related to administration of the study drug. Relationship is ordered as follows: unrelated, possibly related, probably related, or definitely related. TEAEs and TEAE severity were classified in accordance with the Medical Dictionary for Regulatory Activities (MedDRA) 13.0 dictionary. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
Time frame: First dose of study drug (Day 0) to End of Follow-up (Week 20 [8 weeks after EOT])
Area Under The Curve (AUC) Of The Change From Baseline To Week 12 In Levels Of Lactate Dehydrogenase (LDH)
The AUC of LDH was calculated by using the change of LDH from baseline values for each participant up to Week 12. For those participants with missing LDH values, the last observation carried forward method (LOCF) was used to impute missing values. Individual AUC values of LDH were summarized and tabulated.
Time frame: Baseline, EOT (Day 84 [Week 12]) or ET
Concentration Of Plasma-free Hemoglobin At Baseline And Week 12
Plasma-free hemoglobin was determined for each participant by using standard laboratory assays. The values of plasma-free hemoglobin were summarized by visit.
Time frame: Baseline, EOT (Day 84 [Week 12]) or ET
Change From Baseline In LDH Levels
Levels of LDH were determined by using standard laboratory assays. LDH values and the change of LDH from baseline were summarized by visit.
Time frame: Baseline, Weeks 1 to 12 or ET
The recruitment period lasted from October 2009 to January 2011. Three sites in the United States of America enrolled a total of 7 participants with paroxysmal nocturnal hemoglobinuria (PNH).
| Milestone | Eculizumab |
|---|---|
| Started | 7 |
| Induction phase | 7 |
| Maintenance phase | 7 |
| Received at least 1 dose of study drug | 7 |
| Intent-to-treat (itt) population | 7 |
| Completed | 7 |
| Not completed | 0 |
Serum concentrations of eculizumab were measured by using a validated enzyme-linked immunosorbent assay (ELISA) method developed at Alexion Pharmaceuticals Bioanalytical Laboratory. The range of the analytical assay was 10 to 600 microgram per milliliter (μg/mL). Peak concentrations were not measured at the early termination (ET) visit.
| μg/mL | Eculizumab |
|---|---|
| Trough concentration | 192.5 (124.2 to 321.1) |
| Peak concentration | 425.4 (220.5 to 566.1) |
A TEAE was defined as any adverse event (AE) not present prior to exposure to eculizumab or any event already present that worsened in either intensity or frequency following exposure to eculizumab. A serious TEAE was defined as any event that resulted in death, was immediately life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect. Related TEAEs were considered by investigators to be definitely, probably, or possibly related to administration of the study drug. Relationship is ordered as follows: unrelated, possibly related, probably related, or definitely related. TEAEs and TEAE severity were classified in accordance with the Medical Dictionary for Regulatory Activities (MedDRA) 13.0 dictionary. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
| Participants | Eculizumab |
|---|---|
| Participants with at least 1 TEAE | 7 |
| Participants with any serious TEAE | 2 |
| Participants with any mild TEAE | 4 |
| Participants with any moderate TEAE | 1 |
| Participants with any severe TEAE | 2 |
| Participants with any unrelated TEAE | 2 |
| Participants with any possibly related TEAE | 3 |
| Participants with any probably related TEAE | 2 |
| Participants with any definitely related TEAE | 0 |
The AUC of LDH was calculated by using the change of LDH from baseline values for each participant up to Week 12. For those participants with missing LDH values, the last observation carried forward method (LOCF) was used to impute missing values. Individual AUC values of LDH were summarized and tabulated.
| Units * Days per Liter (U*Day/L) | Eculizumab |
|---|---|
| Area Under The Curve (AUC) Of The Change From Baseline To Week 12 In Levels Of Lactate Dehydrogenase (LDH) | -60634 ± 72916 |
Plasma-free hemoglobin was determined for each participant by using standard laboratory assays. The values of plasma-free hemoglobin were summarized by visit.
| mg per deciliter (mg/dL) | Eculizumab |
|---|---|
| Baseline | 17.70 ± 19.091 |
| Week 12 | 7.44 ± 3.145 |
Levels of LDH were determined by using standard laboratory assays. LDH values and the change of LDH from baseline were summarized by visit.
| U/L | Eculizumab |
|---|---|
| Baseline | 1020 ± 967 |
| Change from baseline at Week 1 | -672 ± 837 |
| Change from baseline at Week 2 | -763 ± 916 |
| Change from baseline at Week 3 | -752 ± 934 |
| Change from baseline at Week 4 | -761 ± 924 |
| Change from baseline at Week 8 | -747 ± 904 |
| Change from baseline at Week 12 | -771 ± 914 |
Collected over First dose of study drug (Day 0) to End of Follow-up (Week 20 [8 weeks after EOT]). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eculizumab | — | 2/7 (28.6%) | 7/7 (100%) |
| Event | Eculizumab |
|---|---|
| MenorrhagiaReproductive system and breast disorders | 1/4 |
| Vaginal haemorrhageReproductive system and breast disorders | 1/4 |
| AnaemiaBlood and lymphatic system disorders | 1/7 |
| Aplastic anaemiaBlood and lymphatic system disorders | 1/7 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/7 |
| HeadacheNervous system disorders | 1/7 |
| Acute sinusitisInfections and infestations | 1/7 |
| Catheter site cellulitisInfections and infestations | 1/7 |
| Otitis media acuteInfections and infestations | 1/7 |
| Event | Eculizumab |
|---|---|
| HeadacheNervous system disorders | 5/7 |
| Abdominal pain upperGastrointestinal disorders | 2/7 |
| PyrexiaGeneral disorders | 2/7 |
| Upper respiratory tract infectionInfections and infestations | 2/7 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/7 |
| Vaginal dischargeReproductive system and breast disorders | 1/4 |
| Vulvovaginal pruritusReproductive system and breast disorders | 1/4 |
| HaemolysisBlood and lymphatic system disorders | 1/7 |
| Lymph node painBlood and lymphatic system disorders | 1/7 |
| DiarrhoeaGastrointestinal disorders | 1/7 |
ITT Population: Participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Eculizumab |
|---|---|
| Mean | 15.01 ± 2.28 |
| Age, Customized(Participants) | Eculizumab |
|---|---|
| Children (2 to 11 years) | 1 |
| Adolescents (12 to 17 years) | 6 |
| Sex: Female, Male(Participants) | Eculizumab |
|---|---|
| Female | 4 |
| Male | 3 |
Ran from Oct 2009 to primary completion in May 2011, 19 months.
Results were first posted in Oct 2018, 7 years 5 months after primary completion. A results delay was requested in Mar 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Alexion Pharmaceuticals, Inc. →